Anti-interleukin-6 therapies for Covid-19: A systematic review, critical appraisal and meta-analysis.
Natl Med J India
; 33(3): 152-157, 2020.
Article
Dans Anglais
| MEDLINE | ID: covidwho-1204310
ABSTRACT
Background:
. Coronavirus disease 2019 (Covid-19) has emerged as a pandemic by end-January 2020. Of the infected patients, 10%-15% may develop severe or critical illness. So far, no definite treatment is available for Covid-19. Cytokine release syndrome may underlie the pathogenesis of severe and critical disease. Anti-interleukin (IL)-6 therapies are being tried to improve clinical outcomes.Methods:
. We did a systematic review to identify the available literature on anti-IL-6 therapies in the treatment of Covid-19 and used the GRADE method to assess the quality of evidence.Results:
. Four case series and 10 case reports were identified. On critical assessment, we found that these studies reported some beneficial effect of anti-IL-6 therapy, but all the studies had a high risk of bias. The pooled estimate showed that 42% of patients improved but with a very wide confidence interval (CI) (95% CI 1%-91%) and substantial heterogeneity (I2 = 95%). The overall quality of evidence was graded as 'very low'.Conclusions:
. Although promising, anti-IL-6 therapy for Covid-19 needs to be tested in randomized controlled trials to provide robust evidence.
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
Interleukine-6
/
Syndrome de libération de cytokines
/
COVID-19
/
/
Anti-inflammatoires
Type d'étude:
Études expérimentales
/
Étude pronostique
/
Essai contrôlé randomisé
/
Révision
/
Examen systématique/Méta-analyse
Les sujets:
Covid long
Limites du sujet:
Humains
langue:
Anglais
Revue:
Natl Med J India
Thème du journal:
Médicament
Année:
2020
Type de document:
Article
Pays d'affiliation:
0970-258X.288119
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS